DrugPatentWatch Database Preview
Drugs in Development Information for Penclomedine
» See Plans and Pricing
What is the development status for investigational drug Penclomedine?
Penclomedine is an investigational drug.
There have been 6 clinical trials for Penclomedine.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Neoplasms, Lymphoma, and Neoplasms, Second Primary. The leading clinical trial sponsors are National Cancer Institute (NCI), DEKK-TEC, Inc., and Sidney Kimmel Comprehensive Cancer Center.
There are sixty-one US patents protecting this investigational drug and five hundred and forty-eight international patents.
Summary for Penclomedine
| US Patents | 61 |
| International Patents | 548 |
| US Patent Applications | 100 |
| WIPO Patent Applications | 91 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2013-09-01) |
| Vendors | 10 |
Recent Clinical Trials for Penclomedine
| Title | Sponsor | Phase |
|---|---|---|
| A Phase I Study of DM-CHOC-PEN in Pediatric and Adolescent Subjects With Advanced Cancers | DEKK-TEC, Inc. | Phase 1 |
| Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain Tumors | Detroit Clinical Research Center, Farmington Hills, Lansing and Owasso, MI | Phase 2 |
| Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain Tumors | Icahn School of Medicine at Mount Sinai | Phase 2 |
Clinical Trial Summary for Penclomedine
Top disease conditions for Penclomedine
Top clinical trial sponsors for Penclomedine
US Patents for Penclomedine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Penclomedine | Start Trial | Methods and systems for predicting cancer outcome | H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL) University of South Florida (Tampa, FL) | Start Trial |
| Penclomedine | Start Trial | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor | Novartis AG (Basel, CH) | Start Trial |
| Penclomedine | Start Trial | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (Melbourne, AU) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Penclomedine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Penclomedine | European Patent Office | EP1894131 | 2025-02-25 | Start Trial |
| Penclomedine | World Intellectual Property Organization (WIPO) | WO2005083128 | 2024-02-25 | Start Trial |
| Penclomedine | World Intellectual Property Organization (WIPO) | WO2006093507 | 2024-02-25 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
